RNTX
Rein Therapeutics Inc.
Price Chart
Latest Quote
$0.92
+0.05 (+5.87%)
Current Price
| Previous Close | $0.86 |
| Open | $0.89 |
| Day High | $0.93 |
| Day Low | $0.86 |
| Volume | 2,056,659 |
Stock Information
| Shares Outstanding | 85.54M |
| Total Debt | $4.92M |
| Cash Equivalents | $4.45M |
| Net Income | $-50.21M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $78.33M |
| EPS (TTM) | $-1.91 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $123.81M |
| Income | $-50.21M |
| Book/sh | $-1.19 |
| Cash/sh | $0.05 |
| Employees | 10 |
Financial Ratios
| Quick Ratio | 0.33 |
| Current Ratio | 0.40 |
| Debt/Eq | 42.47 |
Returns & Margins
| ROA | -32.10% |
| ROE | -163.36% |
Ownership
| Insider Ownership | 5.50% |
| Institutional Ownership | 24.62% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | -0.77 |
Analyst Data
| Recommendation | none |
| Target Price | $8.00 |
Technical Indicators
| SMA20 | $0.99 |
| SMA50 | $1.22 |
| SMA200 | $1.28 |
| RSI | 25.00 |
| ATR | 0.0811 |
| Shares Float | 71.50M |
| Short Float | 0.48% |
| Short Ratio | 0.27 |
| Volatility | 1.35 |
| Rel Volume | 3.40 |
Performance History
| Week | -1.08% |
| Month | -7.94% |
| Quarter | -29.54% |
| 6 Months | -32.15% |
| YTD | -26.72% |
| Year | -49.11% |
| 3 Years | -49.39% |
| 5 Years | -96.66% |
| 10 Years | -99.58% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.92 | 2,056,700 |
| 2026-06-17 | $0.87 | 749,700 |
| 2026-06-16 | $0.94 | 1,261,800 |
| 2026-06-15 | $0.94 | 594,700 |
| 2026-06-12 | $0.96 | 721,500 |
| 2026-06-11 | $0.93 | 370,300 |
| 2026-06-10 | $0.92 | 248,600 |
| 2026-06-09 | $0.92 | 391,900 |
| 2026-06-08 | $0.95 | 453,100 |
| 2026-06-05 | $0.94 | 1,124,000 |
| 2026-06-04 | $1.02 | 441,600 |
| 2026-06-03 | $1.02 | 407,300 |
| 2026-06-02 | $1.03 | 314,300 |
| 2026-06-01 | $1.07 | 491,900 |
| 2026-05-29 | $1.11 | 545,300 |
| 2026-05-28 | $1.11 | 425,400 |
| 2026-05-27 | $1.06 | 148,700 |
| 2026-05-26 | $1.07 | 349,700 |
| 2026-05-22 | $1.03 | 390,000 |
| 2026-05-21 | $1.04 | 597,000 |
| 2026-05-20 | $0.97 | 602,100 |
| 2026-05-19 | $1.00 | 986,100 |
About Rein Therapeutics Inc.
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel, which is in preclinical trial phase for the treatment of cystic fibrosis. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $21,931,000 | $28,112,000 | $15,348,000 | $27,647,000 |
| Other Income Expense | $-28,652,000 | $-36,315,000 | $-728,000 | $318,000 |
| Other Non Operating Income Expenses | $48,000 | $685,000 | - | $318,000 |
| Operating Expense | $21,931,000 | $28,112,000 | $15,348,000 | $27,647,000 |
| General And Administrative Expense | $10,902,000 | $13,864,000 | $11,357,000 | $9,680,000 |
| Net Non Operating Interest Income Expense | - | $400,000 | $400,000 | $300,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-49,871,000 | $-62,883,000 | $-15,732,000 | $-27,329,000 |
| Normalized Income | $-21,572,800 | $-26,771,000 | $-15,004,000 | $-27,329,000 |
| Net Income From Continuing And Discontinued Operation | $-49,871,000 | $-62,883,000 | $-15,732,000 | $-27,329,000 |
| Total Operating Income As Reported | $-50,631,000 | $-65,112,000 | $-16,276,000 | $-27,647,000 |
| Net Income Common Stockholders | $-49,871,000 | $-62,883,000 | $-15,732,000 | $-27,329,000 |
| Net Income | $-49,871,000 | $-62,883,000 | $-15,732,000 | $-27,329,000 |
| Net Income Including Noncontrolling Interests | $-49,871,000 | $-62,883,000 | $-15,676,000 | $-27,329,000 |
| Net Income Continuous Operations | $-49,871,000 | $-62,883,000 | $-15,676,000 | $-27,329,000 |
| Pretax Income | $-50,583,000 | $-64,427,000 | $-15,676,000 | $-27,329,000 |
| Special Income Charges | $-28,700,000 | $-37,000,000 | $-928,000 | $0 |
| Operating Income | $-21,931,000 | $-28,112,000 | $-15,348,000 | $-27,647,000 |
| Net Interest Income | - | $400,000 | $400,000 | $300,000 |
| Interest Income | - | $400,000 | $400,000 | $300,000 |
| Interest Income Non Operating | - | $400,000 | $400,000 | $300,000 |
| Per Share | ||||
| Diluted EPS | $-1.96 | $-3.51 | $-3.42 | $-6.02 |
| Basic EPS | $-1.96 | $-3.51 | $-3.42 | $-6.02 |
| Other | ||||
| Tax Effect Of Unusual Items | $-401,800 | $-888,000 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $6,770,000 | $8,951,000 | $-14,501,000 | $-27,478,000 |
| Total Unusual Items | $-28,700,000 | $-37,000,000 | $-728,000 | $0 |
| Total Unusual Items Excluding Goodwill | $-28,700,000 | $-37,000,000 | $-728,000 | $0 |
| Reconciled Depreciation | $1,000 | $63,000 | $119,000 | $169,000 |
| EBITDA (Bullshit earnings) | $-21,930,000 | $-28,049,000 | $-15,229,000 | $-27,478,000 |
| EBIT | $-21,931,000 | $-28,112,000 | $-15,348,000 | $-27,647,000 |
| Diluted Average Shares | $25,444,795 | $17,938,899 | $4,598,715 | $4,539,318 |
| Basic Average Shares | $25,444,795 | $17,938,899 | $4,598,715 | $4,539,318 |
| Diluted NI Availto Com Stockholders | $-49,871,000 | $-62,883,000 | $-15,732,000 | $-27,329,000 |
| Tax Provision | $-712,000 | $-1,544,000 | $0 | - |
| Impairment Of Capital Assets | $28,700,000 | $37,000,000 | $0 | - |
| Research And Development | $11,029,000 | $14,248,000 | $3,991,000 | $17,967,000 |
| Selling General And Administration | $10,902,000 | $13,864,000 | $11,357,000 | $9,680,000 |
| Other Gand A | $7,154,000 | $8,399,000 | $8,634,000 | $6,612,000 |
| Salaries And Wages | $3,748,000 | $5,465,000 | $2,723,000 | $3,068,000 |
| Restructuring And Mergern Acquisition | - | $0 | $928,000 | $0 |
| Gain On Sale Of Security | - | $300,000 | $200,000 | - |
| Gain On Sale Of Ppe | - | - | - | - |
| Other Special Charges | - | - | - | - |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-47,917,000 | $-39,143,000 | $-78,643,000 | $18,623,000 |
| Total Assets | $24,158,000 | $62,190,000 | $106,008,000 | $22,007,000 |
| Total Non Current Assets | $19,832,000 | $48,533,000 | $87,742,000 | $134,000 |
| Other Non Current Assets | $2,000 | $2,000 | $53,000 | $24,000 |
| Goodwill And Other Intangible Assets | $19,830,000 | $48,530,000 | $85,530,000 | $0 |
| Other Intangible Assets | $13,500,000 | $42,200,000 | $79,200,000 | - |
| Current Assets | $4,326,000 | $13,657,000 | $18,266,000 | $21,873,000 |
| Other Current Assets | $881,000 | $676,000 | $721,000 | $606,000 |
| Prepaid Assets | $230,000 | $116,000 | $207,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $3,215,000 | $12,865,000 | $17,313,000 | $21,242,000 |
| Cash And Cash Equivalents | $3,215,000 | $12,865,000 | $17,313,000 | $5,194,000 |
| Cash Equivalents | $3,134,000 | $10,880,000 | $10,322,000 | $1,661,000 |
| Cash Financial | $81,000 | $1,985,000 | $6,991,000 | $3,533,000 |
| Non Current Prepaid Assets | - | $0 | $2,140,000 | $0 |
| Restricted Cash | - | $0 | $25,000 | $25,000 |
| Debt | ||||
| Total Debt | - | $0 | $48,000 | $33,000 |
| Current Debt And Capital Lease Obligation | - | - | $48,000 | $33,000 |
| Long Term Debt And Capital Lease Obligation | - | - | - | $0 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $52,245,000 | $52,803,000 | $99,121,000 | $3,384,000 |
| Total Non Current Liabilities Net Minority Interest | $46,065,000 | $47,054,000 | $94,736,000 | $0 |
| Non Current Deferred Liabilities | $1,060,000 | $1,772,000 | $3,326,000 | $0 |
| Non Current Deferred Taxes Liabilities | $1,060,000 | $1,772,000 | $3,326,000 | $0 |
| Current Liabilities | $6,180,000 | $5,749,000 | $4,385,000 | $3,384,000 |
| Other Current Liabilities | $98,000 | $122,000 | $206,000 | $181,000 |
| Payables And Accrued Expenses | $6,082,000 | $5,627,000 | $4,131,000 | $3,170,000 |
| Payables | $3,976,000 | $911,000 | $1,190,000 | $1,720,000 |
| Accounts Payable | $3,976,000 | $911,000 | $1,190,000 | $1,720,000 |
| Other Non Current Liabilities | - | $277,000 | - | - |
| Equity | ||||
| Common Stock Equity | $-28,087,000 | $9,387,000 | $6,887,000 | $18,623,000 |
| Total Equity Gross Minority Interest | $-28,087,000 | $9,387,000 | $6,887,000 | $18,623,000 |
| Stockholders Equity | $-28,087,000 | $9,387,000 | $6,887,000 | $18,623,000 |
| Gains Losses Not Affecting Retained Earnings | $-62,000 | $-18,000 | $-63,000 | $-48,000 |
| Other Equity Adjustments | $-62,000 | $-18,000 | $-63,000 | $-48,000 |
| Retained Earnings | $-401,271,000 | $-351,400,000 | $-288,517,000 | $-272,785,000 |
| Preferred Securities Outside Stock Equity | $45,005,000 | $45,005,000 | $91,410,000 | $0 |
| Other | ||||
| Ordinary Shares Number | $27,550,222 | $21,666,012 | $4,885,512 | $4,541,167 |
| Share Issued | $27,550,222 | $21,666,012 | $4,885,512 | $4,541,167 |
| Tangible Book Value | $-47,917,000 | $-39,143,000 | $-78,643,000 | $18,623,000 |
| Invested Capital | $-28,087,000 | $9,387,000 | $6,887,000 | $18,623,000 |
| Working Capital | $-1,854,000 | $7,908,000 | $13,881,000 | $18,489,000 |
| Total Capitalization | $-28,087,000 | $9,387,000 | $6,887,000 | $18,623,000 |
| Additional Paid In Capital | $373,133,000 | $360,697,000 | $295,376,000 | $291,365,000 |
| Capital Stock | $113,000 | $108,000 | $91,000 | $91,000 |
| Common Stock | $113,000 | $108,000 | $91,000 | $91,000 |
| Current Accrued Expenses | $2,106,000 | $4,716,000 | $2,941,000 | $1,450,000 |
| Goodwill | $6,330,000 | $6,330,000 | $6,330,000 | $0 |
| Net PPE | $0 | $1,000 | $19,000 | $110,000 |
| Capital Lease Obligations | - | $0 | $48,000 | $33,000 |
| Current Capital Lease Obligation | - | $0 | $48,000 | $33,000 |
| Treasury Shares Number | - | - | $0 | - |
| Accumulated Depreciation | - | - | $-358,000 | $-270,000 |
| Gross PPE | - | - | $377,000 | $380,000 |
| Machinery Furniture Equipment | - | - | $377,000 | $340,000 |
| Buildings And Improvements | - | - | $0 | $40,000 |
| Properties | - | - | $0 | $0 |
| Other Short Term Investments | - | - | $0 | $16,048,000 |
| Preferred Stock | - | - | - | $0 |
| Long Term Capital Lease Obligation | - | - | - | $0 |
| Other Properties | - | - | - | - |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-19,361,000 | $-22,291,000 | $-19,808,000 | $-24,865,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-19,361,000 | $-22,291,000 | $-19,808,000 | $-24,865,000 |
| Cash Flow From Continuing Operating Activities | $-19,361,000 | $-22,291,000 | $-19,808,000 | $-24,865,000 |
| Operating Gains Losses | - | - | $-36,000 | - |
| Investing Activities | ||||
| Investing Cash Flow | - | $0 | $16,196,000 | $26,459,000 |
| Cash Flow From Continuing Investing Activities | - | $0 | $16,196,000 | $26,459,000 |
| Capital Expenditure | - | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $3,414,000 | $10,645,000 | $0 | $0 |
| Financing Cash Flow | $9,755,000 | $17,818,000 | $15,794,000 | $0 |
| Cash Flow From Continuing Financing Activities | $9,755,000 | $17,818,000 | $15,794,000 | $0 |
| Net Other Financing Charges | $2,850,000 | - | $15,794,000 | - |
| Net Common Stock Issuance | $3,414,000 | $10,645,000 | $0 | $0 |
| Common Stock Issuance | $3,414,000 | $10,645,000 | $0 | $0 |
| Other | ||||
| End Cash Position | $3,215,000 | $12,865,000 | $17,338,000 | $5,219,000 |
| Beginning Cash Position | $12,865,000 | $17,338,000 | $5,219,000 | $3,625,000 |
| Effect Of Exchange Rate Changes | $-44,000 | $0 | $-63,000 | $0 |
| Changes In Cash | $-9,606,000 | $-4,473,000 | $12,182,000 | $1,594,000 |
| Proceeds From Stock Option Exercised | $3,491,000 | $7,173,000 | $0 | $0 |
| Change In Working Capital | $-865,000 | $2,412,000 | $-5,381,000 | $420,000 |
| Change In Other Working Capital | $-712,000 | $-1,554,000 | - | - |
| Change In Other Current Liabilities | $-277,000 | $229,000 | $-65,000 | $-129,000 |
| Change In Other Current Assets | $0 | $2,191,000 | $-3,000 | $0 |
| Change In Payables And Accrued Expense | $443,000 | $1,412,000 | $-5,364,000 | $-1,064,000 |
| Change In Accrued Expense | $-2,622,000 | $1,691,000 | $-382,000 | $-1,574,000 |
| Change In Payable | $3,065,000 | $-279,000 | $-4,982,000 | $510,000 |
| Change In Account Payable | $3,065,000 | $-279,000 | $-4,982,000 | $510,000 |
| Change In Prepaid Assets | $-319,000 | $134,000 | $51,000 | $1,613,000 |
| Other Non Cash Items | $450,000 | - | - | - |
| Stock Based Compensation | $2,224,000 | $1,117,000 | $1,190,000 | $2,083,000 |
| Asset Impairment Charge | $28,700,000 | $37,000,000 | $0 | - |
| Depreciation Amortization Depletion | $1,000 | $63,000 | $119,000 | $169,000 |
| Depreciation And Amortization | $1,000 | $63,000 | $119,000 | $169,000 |
| Net Income From Continuing Operations | $-49,871,000 | $-62,883,000 | $-15,732,000 | $-27,329,000 |
| Net Investment Purchase And Sale | - | $0 | $16,250,000 | $26,459,000 |
| Sale Of Investment | - | $0 | $16,250,000 | $48,309,000 |
| Net Business Purchase And Sale | - | $0 | $-96,000 | $0 |
| Purchase Of Business | - | $0 | $-96,000 | $0 |
| Net PPE Purchase And Sale | - | $0 | $42,000 | $0 |
| Sale Of PPE | - | $0 | $42,000 | $0 |
| Amortization Of Securities | - | $0 | $32,000 | $-208,000 |
| Gain Loss On Sale Of PPE | - | $0 | $-36,000 | $0 |
| Purchase Of Investment | - | - | $0 | $-21,850,000 |
| Purchase Of PPE | - | - | - | $0 |
| Issuance Of Debt | - | - | - | - |
| Net Issuance Payments Of Debt | - | - | - | - |
| Net Long Term Debt Issuance | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
Fetched: 2026-06-17